Premium
Combination therapy with glatiramer acetate (copolymer‐1) and a type I interferon (IFN‐α) does not improve experimental autoimmune encephalomyelitis
Author(s) -
Brod Staley A.,
Lindsey J. William,
Wolinsky Jerry S.
Publication year - 2000
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/1531-8249(200001)47:1<127::aid-ana22>3.0.co;2-1
Subject(s) - glatiramer acetate , experimental autoimmune encephalomyelitis , medicine , interferon , multiple sclerosis , alpha interferon , adverse effect , immunology , pharmacology , encephalomyelitis
We sought to determine whether combinations of glatiramer acetate and parenteral or ingested type I interferon were synergistic in experimental autoimmune encephalomyelitis. Glatiramer acetate, subcutaneous murine interferon‐α, or ingested murine interferon‐α individually improved clinical scores. In contrast, glatiramer acetate in conjunction with either subcutaneous or ingested interferon‐α did not improve clinical scores compared with control. These data suggest that clinical trials designed to test a possible synergistic effect of glatiramer acetate and type I interferon in humans should be designed to detect possible adverse effects of this combination of immunomodulatory agents. Ann Neurol 2000; 47:127–131